Do GLP-1 drugs raise gallbladder risk? A 156,000-patient study

If you have felt a sharp ache under your right ribs since starting Ozempic or Wegovy, your gallbladder is worth a closer look. A new cohort study of 156,376 people with type 2 diabetes found that GLP-1 medications modestly raise the odds of gallstones and related biliary problems, and it puts an actual number on how much. The short version: the risk is real but small, and most of it is manageable without stopping the drug.

The short answer

In a propensity-matched cohort of 156,376 adults with type 2 diabetes, GLP-1 users had roughly 40 to 50 percent higher odds of gallstones, gallbladder inflammation, and gallbladder removal over three years. The absolute risk stayed low, acute pancreatitis did not rise, and the practical levers are a steadier pace of weight loss and knowing the warning signs.

What the 156,000-patient study actually found

The study, published in the United European Gastroenterology Journal in June 2026, pulled records from the TriNetX US network: 43,077 GLP-1 users and 113,299 people with type 2 diabetes who were not on a GLP-1. After propensity matching to balance age, weight, and other risk factors, the researchers compared 39,140 people in each group over two and three years. Matching this way is what separates this study from a raw safety signal. It lines up similar patients and then watches what happens next.

Over three years, GLP-1 users had higher adjusted odds of three gallbladder outcomes:

• Gallstones (cholelithiasis or stones in the bile duct): adjusted odds ratio 1.43 (95% CI 1.24 to 1.63), about 43 percent higher odds.
• Cholecystitis, meaning an inflamed or infected gallbladder: adjusted odds ratio 1.45 (95% CI 1.14 to 1.83).
• Cholecystectomy, meaning surgical removal of the gallbladder: adjusted odds ratio 1.54 (95% CI 1.17 to 2.02).

Two details matter for how you read those numbers. First, the increase was larger in people who also had obesity, where the combined gallbladder risk rose to an adjusted odds ratio of 1.59 (95% CI 1.34 to 1.86). Second, the risk built over time. Cholecystitis was not statistically higher at two years but was by three, which fits the idea that this is a slow process, not a first-week reaction. An odds ratio near 1.4 is a meaningful bump on top of a baseline that is already fairly common, not a warning that most users will develop gallstones. Most will not.

Does it matter which GLP-1 you take?

The researchers broke the risk down by individual drug, and the picture was not uniform. The increase was statistically clear for semaglutide (combined gallbladder risk adjusted odds ratio 1.51, 95% CI 1.28 to 1.78) and for dulaglutide (adjusted odds ratio 1.58, 95% CI 1.36 to 1.85, with a notably higher bile-duct stone signal at 2.35). Liraglutide (1.11) and exenatide (1.21) did not show a statistically significant rise.

Read that carefully before you ask your prescriber to switch. The authors caution that the per-drug analyses had fewer events and may be underpowered, so "no clear signal" for liraglutide and exenatide is not the same as "proven safe." It is also worth knowing that an earlier pharmacovigilance analysis of FDA adverse-event reports ranked the drugs differently, with liraglutide topping the reporting signal. That is not a contradiction so much as a lesson in evidence quality: a spontaneous-reporting signal reflects what gets reported, while a matched cohort follows real patients forward and estimates an actual rate. We cover the pharmacovigilance side in our FAERS analysis of 1,829 gallbladder cases. Which specific agent is right for you is a prescriber decision that weighs far more than gallbladder odds.

The reassuring part: pancreatitis did not go up

Pancreatitis is the fear that keeps a lot of people awake, so this is worth stating plainly. In the same cohort, acute pancreatitis was not higher in GLP-1 users (adjusted odds ratio 0.82, 95% CI 0.63 to 1.04), a result that did not reach statistical significance. In other words, the gallbladder signal did not drag a pancreatitis signal along with it. That lines up with larger reviews of the pancreas question, which we walk through in our piece on whether Ozempic causes pancreatitis. Gallbladder risk and pancreas risk are separate questions, and this study only moved one of them.

Why GLP-1 medications strain the gallbladder

Two mechanisms do most of the work. The first is rapid weight loss itself. When you lose weight quickly, your liver dumps more cholesterol into bile, which makes stones easier to form. This is not unique to GLP-1 drugs; the same thing happens after bariatric surgery and crash diets. The second is that GLP-1 signaling slows how often the gallbladder squeezes, so bile sits longer and can thicken into sludge and then stones. For the deeper chemistry, see why GLP-1 medications cause gallbladder problems.

The study also flagged which background factors independently raised biliary risk: steatotic (fatty) liver disease (hazard ratio 1.47), alcohol use (hazard ratio 2.23), and obesity (hazard ratio 1.30). One honest caveat belongs here. GLP-1 users in this cohort had about 60 percent more abdominal imaging than the comparison group (adjusted odds ratio 1.60 for imaging). Some of the extra stones were probably found simply because doctors looked more often. That detection effect means the true excess may be a little smaller than the raw odds ratio suggests. Early findings like these describe an association, not proof of cause.

Warning signs and when to call your doctor

Most gallstones are silent and never cause trouble. The ones that matter announce themselves. Get checked promptly if you notice:

1. A steady, gripping pain in the upper right abdomen or the pit of your stomach, often starting after a fatty meal and lasting more than a few minutes.
2. Pain that radiates to your right shoulder blade or the middle of your back.
3. Nausea or vomiting that comes with the pain rather than the ordinary early-treatment queasiness.
4. Fever or chills, which can signal an infected gallbladder.
5. Yellowing of the skin or eyes, dark urine, or pale stools, which can mean a stone is blocking a duct.

Sudden severe abdominal pain, a fever with that pain, or any yellowing of the eyes or skin is a same-day medical problem, not something to ride out. A blocked bile duct or an infected gallbladder can escalate quickly.

What this means if you take a GLP-1

You do not need to quit your medication over this study. The absolute risk is low, the benefit of the drug for many people is large, and gallbladder problems are usually treatable. What you can influence is the setup. Because the pace of weight loss is one of the main drivers, losing weight steadily rather than as fast as possible, eating enough protein, and not skipping meals for long stretches all work in your favor. Staying on top of the ordinary GLP-1 side effects helps too, and our guide on managing GLP-1 side effects without stopping the drug covers the day-to-day tactics.

Two things to be clear about. No supplement treats or prevents gallstones, and none replaces medical care for an acute attack. Where supplements do fit is the nutrient gap that rapid weight loss opens up, since eating far less can leave you short on vitamin B12, vitamin D, iron, and other micronutrients. A sensible monitoring plan matters, and our vitamin monitoring guide for GLP-1 users lays out what to test. Closing that gap is exactly the problem GLP-1 Shield is built to solve: steady nutrient support so the fatigue and deficiencies that come with fast weight loss do not pile on top of everything else. GLP-1 medications are prescription-only and should be used under medical supervision, and any decision about your gallbladder belongs with your doctor.

Frequently asked questions

How much do GLP-1 drugs raise gallbladder risk?

In a propensity-matched cohort of 156,376 adults with type 2 diabetes (published in the United European Gastroenterology Journal, 2026), GLP-1 users had about 40 to 50 percent higher odds of gallstones (adjusted odds ratio 1.43), gallbladder inflammation (1.45), and gallbladder removal (1.54) over three years. That is a relative increase on a low baseline, so most users will not develop gallbladder problems, and the risk builds gradually rather than all at once.

Will I need my gallbladder removed if I get stones on a GLP-1?

Usually not. Most gallstones are silent and are left alone. In the 156,376-patient cohort, gallbladder removal (cholecystectomy) rose modestly (adjusted odds ratio 1.54 over three years), but surgery is generally reserved for stones that cause repeated pain or complications. If you have symptoms, your doctor decides based on your case, not on the medication alone.

Did this study find a higher pancreatitis risk too?

No. In the same cohort, acute pancreatitis was not significantly higher in GLP-1 users (adjusted odds ratio 0.82, 95% CI 0.63 to 1.04) over three years, even though gallbladder events rose. Gallbladder risk and pancreatitis risk are separate questions, and this study only moved the gallbladder one.

Should I stop or switch my GLP-1 if I am worried about my gallbladder?

Do not stop or switch on your own. For most people the gallbladder risk is small and does not outweigh the medication's benefits, and per-drug differences in this study may be underpowered. If you develop warning signs like steady upper-right abdominal pain, fever, or yellowing eyes, contact your prescriber, who can weigh monitoring, imaging, or a change against your full picture.